The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10651 malaria professionals are enjoying the free benefits of MalariaWorld today

artesunate

The Presence of Leukocytes in Ex Vivo Assays Significantly Increases the 50-Percent Inhibitory Concentrations of Artesunate and Chloroquine against Plasmodium vivax and Plasmodium falciparum

March 1, 2011 - 06:34 -- Kabogo Ndegwa
Author(s): 
S. Kaewpongsri, K. Sriprawat, R. Suwanarusk, D. E. Kyle, U. Lek-Uthai, M. Leimanis, K. M. Lwin, A. P. Phyo, J. Zwang, B. Russell, F. Nosten, and L. Renia
Reference: 
Antimicrobial Agents and Chemotherapy, March 2011, p. 1300-1304, Vol. 55, No. 3

Plasmodium species ex vivo sensitivity assay protocols differ in the requirement for leukocyte removal before culturing.

Medical Treatment: 

Efficacy and safety of mefloquine, artesunate, mefloquine–artesunate, tribendimidine, and praziquantel in patients with Opisthorchis viverrini: a randomised, exploratory, open-label, phase 2 trial

January 26, 2011 - 09:47 -- Patrick Sampao
Author(s): 
Phonepasong Soukhathammavong, Peter Odermatt, Jennifer Keiser, et al.
Reference: 
The Lancet Infectious Diseases, Volume 11, Issue 2, February 2011, Pages 110-118

We did a randomised open-label trial between February and April, 2010, in the Saysetha district, Attapeu Province, Laos. Eligible patients were school children aged 10–15 years who had O viverrini infections.

Prereferral rectal artesunate for treatment of severe childhood malaria: a cost-effectiveness analysis

December 6, 2010 - 12:56 -- Patrick Sampao
Author(s): 
Yeşim Tozan, Eili Y Klein, Sarah Darley, Rajashree Panicker, Ramanan Laxminarayan, Joel G Breman
Reference: 
The Lancet, Volume 376, Issue 9756, 4 December 2010-10 December 2010, Pages 1910-1915

The analysis assessed how the cost-effectiveness results changed with low (25%), moderate (50%), high (75%), and full (100%) referral compliance and intervention uptake.

Person: 
Medical Condition: 
Medical Treatment: 

Open Access | Absence of association between pyronaridine in vitro responses and polymorphisms in genes involved in quinoline resistance in Plasmodium falciparum

December 1, 2010 - 05:15 -- Kabogo Ndegwa
Author(s): 
Pradines B, Briolant S, Henry M, Oeuvray C, Baret E, Amalvict R, Didillon E, Rogier C
Reference: 
Malaria Journal 2010, 9:339 (25 November 2010)

There was an absence of cross-resistance between pyronaridine and quinolines, and the IC50 values for pyronaridine were found to be unrelated to mutations in the transport protein genes pfcrt, pfmdr1, pfmrp or pfnhe-1, known to be involved in quinoline resistance.

Medical Treatment: 

Fast Track: Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial

November 15, 2010 - 13:43 -- Patrick Sampao
Author(s): 
Arjen M Dondorp, Caterina I Fanello, Juliet Mwanga-Amumpaire et al.
Reference: 
The Lancet, Volume 376, Issue 9753, 13 November 2010-19 November 2010, Pages 1647-1657

These data, together with a meta-analysis of all trials comparing artesunate and quinine, strongly suggest that parenteral artesunate should replace quinine as the treatment of choice for severe falciparum malaria worldwide.

Continent: 
Medical Condition: 
Medical Treatment: 

Open Access | Dispatch: Artesunate Misuse and Plasmodium falciparum Malaria in Traveler Returning from Africa

September 24, 2010 - 07:35 -- Patrick Sampao
Author(s): 
Dea Shahinas, Rachel Lau, Krishna Khairnar, David Hancock, and Dylan R. Pillai
Reference: 
Emerging Infectious Diseases, Volume 16, Number 10–October 2010

Plasmodium falciparum malaria developed in an African-born traveler who returned to Canada after visiting Nigeria.

Person: 
Continent: 
Medical Condition: 
Medical Treatment: 

Erratum: New Fixed-Dose Artesunate-Mefloquine Formulation against Multidrug-Resistant Plasmodium falciparumin Adults: a Comparative Phase IIb Safety and Pharmacokinetic Study with Standard-Dose Nonfixed Artesunate plus Mefloquine

September 21, 2010 - 08:47 -- Kabogo Ndegwa
Author(s): 
S. Krudsood, S. Looareesuwan, N. Tangpukdee, P. Wilairatana, W. Phumratanaprapin, W. Leowattana, K. Chalermrut, S. Ramanathan, V. Navaratnam, P. Olliaro, M. Vaillant, J. R. Kiechel, and W. R. J. Taylor
Reference: 
Antimicrobial Agents and Chemotherapy, October 2010, p. 4526, Vol. 54, No. 10

Giemsa-stained thick and thin blood films were examined at baseline; every 6 hours for the first 3 days;

Person: 
Medical Condition: 
Medical Treatment: 

Short Communication: Comparison of artesunate and quinine in the treatment of Sudanese children with severe Plasmodium falciparum malaria

September 20, 2010 - 13:25 -- Patrick Sampao
Author(s): 
Hatim G. Eltahir, Abubaker A. Omer, Ayoub A. Mohamed, Ishag Adam
Reference: 
Transactions of the Royal Society of Tropical Medicine and Hygiene, Volume 104, Issue 10, October 2010, Pages 684-686

Sixty-six children presenting to Singa hospital, Sudan with different manifestations of severe Plasmodium falciparum malaria were randomly divided into two well-matched groups (33 in each arm) to receive either intravenous artesunate 2•4 mg/kg at 0, 12, and 24 hours, then daily, or intravenous quinine 20 mg/kg initially then 10 mg/kg three times a day.

Person: 
Country: 
Medical Condition: 
Medical Treatment: 

Open Access | Cost Effectiveness of Seasonal Intermittent Preventive Treatment Using Amodiaquine & Artesunate or Sulphadoxine-Pyrimethamine in Ghanaian Children

August 20, 2010 - 12:07 -- Kabogo Ndegwa
Author(s): 
Lesong Conteh, Edith Patouillard, Margaret Kweku, Rosa Legood, Brian Greenwood, Daniel Chandramohan
Reference: 
PLoS ONE 5(8): e12223

We demonstrate how cost-effective IPTc is using three different drug regimens and the possibilities for reducing costs further if the intervention was to be scaled up to the district level. The need for effective training, drug delivery channels and supervision to support a strong network of community based volunteers is emphasised.

Person: 
Country: 
Medical Condition: 

Investigations into the Role of the Plasmodium falciparum SERCA (PfATP6) L263E Mutation in Artemisinin Action and Resistance

August 18, 2010 - 12:52 -- Kabogo Ndegwa
Author(s): 
Stephanie Gaw Valderramos, Daniel Scanfeld, Anne-Catrin Uhlemann, David A. Fidock, and Sanjeev Krishna
Reference: 
Antimicrobial Agents and Chemotherapy, September 2010, p. 3842-3852, Vol. 54, No. 9

Artemisinin-based combination therapies (ACTs) are highly effective for the treatment of Plasmodium falciparum malaria, yet their sustained efficacy is threatened by the potential spread of parasite resistance.

Medical Treatment: 

Pages

Subscribe to RSS - artesunate